A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS)
Principal Investigator

August 2020-present

BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer. NCT04264702, SIGNATERA,
Sub-PI

July 2020-Present

An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants with Advanced Non-Small Cell Lung Cancer. NCT04077463, Janssen Research Development.  Sub PI

July 2020-Present

A Phase 3 Randomized, Double-Blind Study of Nivolumab or Placebo in Combination with Docetaxel, in Men with Metastatic Castration-resistant Prostate Cancer (CheckMate 7DX: CHECKpoint pathway and nivoluMAB clinical Trial Evaluation 7DX). NCT04100018,  Sub-PI

July 2020-Present

A Randomized, Multi-center, Double-blinded, Placebo-controlled Phase 3 Study of Nivolumab and Ipilimumab, Nivolumab Monotherapy, or Placebo in Combination with Trans-arterial ChemoEmbolization (TACE) in Patients with Intermediatestage Hepatocellular Carcinoma (HCC). NCT04340193
Sub-PI

June 2020-Present

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib Versus Gemcitabine with Cisplatin in Subjects With Advanced/Metastatic or Inoperable Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations: the PROOF Trial. NCT03773302, QED Therapeutics.
Sub-PI
A Phase 1b Study of Venetoclax and Capecitabine In Subjects with Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Experienced Disease Progression During or After CDK4/6 Inhibitor Therapy. NCT04274933, AbbVie.
Principal Investigator

January 2020-Present

Randomized, Open-label, 2-Arm, Multicenter, Phase 3 Study of Venetoclax and Azacitidine Versus Best Supportive Care as Maintenance Therapy for Patients with Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy (VIALE-M). NCT04102020, AbbVie.
Principal Investigator

January 2020-Present

A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Chemoradiotherapy (CRT) versus CRT Alone in Participants with Muscle-invasive Bladder Cancer (MIBC) (KEYNOTE-992). NCT04241185, Merck Sharp & Dohme. Sub-PI

November 2019-Present

A phase 2 study of olaparib in combination with pembrolizumab in participants with previously treated Homologous Recombination Repair Mutation and/or Homologous Recombination Repair Deficiency positive advance cancer Sub-PI

October 2019-Present

A multicenter Phase 1, Open -label dose escalation study of the safety, tolerability, and pharmacokinetics of ABBV-368 as a single agent and combination in subjects with locally advance or metastatic solid tumors Principal Investigator

September 2019-Present

A Phase 1b, Multicenter, Randomized, Blinded, Placebo-controlled Study to Evaluate the Efficacy of Guselkumab in Subjects with Familial Adenomatous Polyposis Janssen CNTO1959COR1001 Sub-PI

M15-999: (August 2019)

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Risankizumab Using a New Formulation for the Treatment of Adult Subjects with Moderate to Severe Plaque Psoriasis Sub-PI

July 2019-Present

A Phase 3b Randomized Clinical Trial of Nivolumab alone, Nivolumab in Combination with Ipilimumab, or an
Investigator’s Choice Chemotherapy in Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer, BMS CA-209-8HW
Sub-PI

January 2019-Present

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety ofTislelizumab (BGB-A317) plus Platinum and Fluoropyrimidine Versus Placebo plus Platinum and Fluoropyrimidine as First-Line Treatment in Patients with LocallyAdvanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Sub-PI

December 2018-Present

A Phase 2, Open-Label, Single-Arm Study of Pamiparib (BGB-290) for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Homologous Recombination Deficiency (HRD) BGB290-202 Sub-PI